About Locus Biosciences
Locus Biosciences is a company based in Raleigh (United States) founded in 2015. Locus Biosciences has raised $67.33 million across 12 funding rounds from investors including Tencent, Illumina and Hercules Capital. The company has 74 employees as of December 31, 2022. Locus Biosciences has completed 1 acquisition, including EpiBiome. Locus Biosciences offers products and services including LOCUS Platform and LBP-EC01. Locus Biosciences operates in a competitive market with competitors including Beam Therapeutics, Spero Therapeutics, eGenesis, Korro Bio and Editas Medicine, among others.
- Headquarter Raleigh, United States
- Employees 74 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Locus Biosciences, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Locus Biosciences
Locus Biosciences offers a comprehensive portfolio of products and services, including LOCUS Platform and LBP-EC01.
AI-driven system for designing engineered bacteriophage therapies for infections.
Targets E. coli infections through precision bacteriophage therapeutics.
People of Locus Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Locus Biosciences
Locus Biosciences has successfully raised a total of $67.33M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $23.9 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Locus Biosciences
Locus Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Tencent, Illumina and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage startups are invested in by Artis Ventures.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for Locus Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Locus Biosciences
Locus Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EpiBiome.
Investment portfolio details for Locus Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule antibiotics are developed for agriculture and human health.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Locus Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Locus Biosciences
Detailed financials for Locus Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Locus Biosciences Comparisons
Peer comparison for Locus Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Locus Biosciences
Locus Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, Spero Therapeutics, eGenesis, Korro Bio and Editas Medicine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
Detailed competitors of Locus Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Locus Biosciences
Complete news archive for Locus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Locus Biosciences
Locus Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Locus Biosciences is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Locus Biosciences is a funded company, having raised a total of $67.33M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Locus Biosciences is 74.
Locus Biosciences was founded in 2015 and is headquartered in Raleigh, United States. Operations focus on the biotechnology sector, where a platform is utilized to design and deliver custom CRISPR-Cas systems targeting specific bacteria. Antimicrobials for infectious diseases are enabled through this approach, alongside therapeutics for inflammatory indications. Research and development activities are centered on advancing precision treatments in these areas.
Locus Biosciences's top competitors include Spero Therapeutics, eGenesis and Melinta Therapeutics.
Locus Biosciences offers LOCUS Platform and LBP-EC01.
Locus Biosciences has made 1 acquisition, including EpiBiome.
Locus Biosciences has 9 investors. Key investors include Tencent, Illumina, Hercules Capital, HHS, and NCBiotech.